The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Open accessAbstract
BACKGROUND: Bococizumab, a humanized monoclonal antibody targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) cholesterol. However, the variability and durability of this effect are uncertain. METHODS: We conducted six parallel, multinational lipid-lowering trials enrolling 4300 patients with hyperlipidemia who were randomly assigned to receive 150 mg of bococizumab or placebo subcutaneously every 2 weeks and who were followed for up to 12 months; 96% were receiving statin therapy at the time of enrollment. The patients were assessed for lipid changes over time, stratified according to the presence or absence of antidrug antibodies detected during the treatment period. RESULTS: At 12 weeks, patients who received bococizumab had a reduction of 54.2% in the LDL cholesterol level from baseline, as compared with an increase of 1.0% among those who received placebo (absolute between-group difference, -55.2 percentage points). Significant between-group differences were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) (P<0.001 for all comparisons). However, high-titer antidrug antibodies developed in a substantial proportion of the patients who received bococizumab, which markedly diminished the magnitude and durability of the reduction in LDL cholesterol levels. In addition, among patients with no antidrug antibodies, there was wide variability in the reduction in LDL cholesterol levels at both 12 weeks and 52 weeks. Major cardiovascular events occurred in 57 patients (2.5%) who received bococizumab and in 55 (2.7%) who received placebo (hazard ratio, 0.96; 95% confidence interval, 0.66 to 1.39; P=0.83). The most common adverse event among patients who received bococizumab was injection-site reaction (12.7 per 100 person-years). CONCLUSIONS: In six multinational trials evaluating bococizumab, antidrug antibodies developed in a large proportion of the patients and significantly attenuated the lowering of LDL cholesterol levels. Wide variation in the relative reduction in cholesterol levels was also observed among patients in whom antidrug antibodies did not develop. (Funded by Pfizer; SPIRE ClinicalTrials.gov numbers, NCT01968954 , NCT01968967 , NCT01968980 , NCT02100514 , NCT02135029 , and NCT02458287 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both alirocumab and evolocumab have also been shown to effectively lower LDL-C levels in patients who are at high CV risk, including those with DM [284].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [284]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701488 · Cited by 624
Self-citationVery Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Self-citationRidker, P. M., Mora, S., & Rose, L. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw046 · Cited by 222
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–369 of 369
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P., & Vandell, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00003-6 · Cited by 3
Zadeh, S. S. T., Chan, D. C., & Watts, G. F. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf160 · Cited by 2
Colangelo, G. S., Ianni, A. D., Cowan, K. J., Sirtori, F. R., & Barbero, L. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300035 · Cited by 2
Naturally Occurring PCSK9 Inhibitors: An Updated Review
Huh, J., & Kim, H. W. (2025) · Molecules · doi:10.3390/molecules30173582 · Cited by 3
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
LDL-Cholesterol Lowering Therapies: An Update
Humphrey, R., & Bowman, L. J. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53219 · Cited by 2
Highlights from ACC.17 scientific sessions
Yılmaz, M. B. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7903 · Cited by 1
PCSK9 Inhibitors: Treating the Right Patients in Daily Practice
King, P. M., & Nicholls, S. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0882-6 · Cited by 1
PCSK-9: papel en las hipercolesterolemias y anticuerpos monoclonales específicos inhibitorios
Ruiz, Á. J. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.08.021 · Cited by 3
PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?
Ward, N. C., & Watts, G. F. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.015 · Cited by 1
Guia prático para a utilização dos inibidores da PCSK9 em Portugal
Fontes‐Carvalho, R., Silva, P. M., Rodrigues, E., Araújo, F., Gavina, C., Ferreira, J., & Morais, J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.05.005 · Cited by 6
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
Katzmann, J. L., Custodis, F., Schirmer, S. H., & Laufs, U. (2022) · Herz · doi:10.1007/s00059-022-05112-y · Cited by 1
Personalized Therapy of Cardiovascular Disorders
Jain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_13 · Cited by 1
Abordagens terapêuticas nas dislipidemias - com ênfase na ldl-c (aterogênica)
Guerra, T. D. R. B., Soares, A. D. C. L., Salviano, B. M., Palermo, M. V. A., Scofano, B. D. S., Netto, M. F. G., Nunes, B. E. M., & Tavares, A. P. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n2-288 · Cited by 1
Li, Z., Zhang, S., Yin, Z., Zhang, W., Sui, Y., Li, J., Dou, K., Qian, J., & Wu, N. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.97 · Cited by 1
Features of lipid-lowering therapy in liver transplant recipients
Кучеров, А. А., Ershova, A. I., Евгеньевич, С. В., & Drapkina, O. M. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3872 · Cited by 1
Zhang, L., Li, Y.-Y., Liu, X.-H., Liu, H.-J., & Xu, Q. (2025) · PLOS One · doi:10.1371/journal.pone.0329676 · Cited by 1
Ruiz, S. P., Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., & Álvarez-Sala, J. L. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.003 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Safety and Tolerability of Sustained Lipid-Lowering Therapy
Leening, M. J. G. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3528 · Cited by 1
PCSK9 Monoclonal Antibody: 12 Years, from Basic Research to Clinical Application
应, 航. (2019) · Advances in Clinical Medicine · doi:10.12677/acm.2019.911194 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 2
PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection
Pandey, P., Zhao, C., & Liu, B. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_12 · Cited by 1
Tuñón, J., Lázaro, A. M. P., López‐Castillo, M., & Aceñaa, Á. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30025-x · Cited by 1
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 1
Joint Analysis of Longitudinal and Time-to-Event Data
Lu, Z., Chigutsa, E., & Tong, X. (2021) · Springer eBooks · doi:10.1007/978-3-319-52677-5_131-1 · Cited by 1
Buetow, B. S., Cappon, G. D., Aschenbrenner, L. M., Updyke, L. W., Torti, V. R., Evans, M., Dalton, S. R., Bailey, S. A., & Bowman, C. (2022) · International Journal of Toxicology · doi:10.1177/10915818221106397 · Cited by 1
Joint Analysis of Longitudinal and Time-to-Event Data
Lu, Z., Chigutsa, E., & Tong, X. (2022) · Springer eBooks · doi:10.1007/978-3-319-52636-2_131 · Cited by 1
Agnihotri, S., Gonzalez-Nolasco, B., Monian, B., Pattijn, S., Ackaert, C., Wu, P., Kettenberger, H., Tourdot, S., Hickling, T. P., Hu, Z., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.08.692993 · Cited by 1
Cardiology update 2017: The first quarter
Umapathy, S. (2017) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_16_17
PCSK9 inhibition – Ready for prime time?
Schumur, S. (2017) · The Southwest Respiratory and Critical Care Chronicles · doi:10.12746/swrccc.v5i21.417
The highs and lows of cardiovascular disease prevention
Stock, J. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.005
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · Cardiologia Croatica · doi:10.15836/ccar2018.79
Gesundheitsökonomische Aspekte der Verschreibung von PCSK9-Hemmern
Dressel, A., Schmidt, B., Schmidt, N., Laufs, U., Fath, F., Grammer, T. B., & März, W. (2018) · CardioVasc · doi:10.1007/s15027-018-1480-2
Morales-Villegas, E., & Ray, K. K. (2019) · Frontiers in cardiovascular drug discovery · doi:10.2174/9781681083995118040007
Novel Therapies for Dyslipidemia
Tafaj-Reddy, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88477
Ruiz, S. P., Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., & Álvarez-Sala, J. L. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.04.002
Maksimov, M. L., Shikaleva, А. А., & Кучаева, А. В. (2019) · doi:10.33920/med-06-2003-04
Masson, W. M., Lobo, M., Huerin, M. S., Molinero, G., Lobo, L., & Nogueira, J. P. (2019) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2018.11.005
Mishra, B., Agarwal, A., Nilima, N., Srivastava, M. V. P., & Vishnu, V. Y. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13669 · Cited by 1
Non-clinical safety evaluations of next-generation therapeutic antibodies
Nihira, K. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22049
Inclisiran, ARN interferente pequeño: un nuevo enfoque para el tratamiento del colesterol
Fragozo-Ramos, M. C., Gómez-Sierra, V., Gómez-Galvis, L. V., Campo, R., Santos, R. D., & Román-Gonzaléz, A. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.21000150
Self-citationSkove, S. L., Le, V. T., & Anderson, J. L. (2023) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2022.1292 · Cited by 1
Cui, J., Zhang, Y., Zhang, W., Li, D., Hong, Z., Zhao, L., Sun, J., Chen, Y., & Zhang, N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01218-2 · Cited by 1
Targeted protein degradation via CAR endocytosis of antigen in T cellsPreprint
Wang, Y., Yin, N., & Peng, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.20.624443
Phung, Q. T., Lee, M. V., Saad, O. M., Cohen, S., Li, Y., Balasz, M., Chen, J., Yin, Z., Zhou, Z., & Lill, J. R. (2025) · doi:10.1002/9781394236145.ch11
Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review
Rodrigues, L. D. S., & Bertanha, M. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2025.0005
Reynolds, N. A., Chen, Y., Higgs, R. E., Calderón, B., Cramer, J. W., Bivi, N., Hodsdon, M. E., Bullock, H. A., Shockley, T. E., Peek, V. L., et al. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01143-5
Wang, X., Wen, D., Chen, Y., Ma, L., & You, C. (2022) · Figshare · doi:10.6084/m9.figshare.20081087
Shear, C. L., Davidson, M. H., Ditmarsch, M., Kastelein, J. J. P., & Szarek, M. J. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100728
Self-citationShubow, S., Abhari, M. R., Ta, A., Florian, J. A., Lee, P., & Wang, Y. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01210-5
Qu, J., Liu, K., Johnson, N., Wagatsuma, K., Su, Y., Du, B., & HE, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1696537
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 1
Irvin, S. C., Wang, Z., Ganguly, S., Choudhary, D., Kanagaraj, M., Liu, N., Isa, F., He, Z., YAN, H. H., Casullo, V. M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769163
Parameswaran, T., Hooper, A. J., & Burnett, J. R. (2026) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2662915
Agnihotri, S., Venkatesh, A., Ramanathan, M. K., & Balu‐Iyer, S. V. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104297
Wang, Y., He, Z., Yin, N., & Peng, M. (2026) · hLife · doi:10.1016/j.hlife.2026.05.003
Li, S. N., Gao, Y. N., Zhu, C.-G., & Li, J. (2026) · Drugs · doi:10.1007/s40265-026-02348-4
Agnihotri, S., Gonzalez-Nolasco, B., Monian, B., Pattijn, S., Ackaert, C., Wu, P., Kettenberger, H., Tourdot, S., Hickling, T. P., Hu, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816949
Cholesterol-lowering and heart failure
Katzmann, J. L., Abdelhamid, M., & Laufs, U. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag185
Milasi, Y. E., Sakhaei, F., & Palizban, A. A. (2026) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_242_25
Farrell, L., MacDonald, L., Wells, G., Grice, S., Saide, K., Meng, X., Betts, C. J., & Naisbitt, D. J. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04557-y
Jawa, V., Tourdot, S., Shivaraju, M., Joubert, M., Balu‐Iyer, S. V., Cox, K., Cheng, M., Chen, Y., Huang, M., Peters, K. B., et al. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104527
A Look At Non-Statin Lipid-Lowering Pharmacological Therapy
Vedernikov, A., Михайлович, М. Е., Vedernikova, S. A., & Vyalkina, Y. A. (2026) · The Russian Archives of Internal Medicine · doi:10.33396/2226-6704-2026-16-5-325-335
Metadata
- Authors
- Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., Revkin, J., Rose, L. M., Santos, R. D., Schwartz, P. F., Shear, C. L., & Yunis, C.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-04-20
- Volume
- 376
- Issue
- 16
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2596676407
- Cited by
- 369
- References
- 14
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 31 · 2022: 33 · 2021: 27 · 2020: 46 · 2019: 50 · 2018: 56 · 2017: 51
- FWCI
- 56.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- bococizumab, PCSK9 inhibitors, antidrug antibodies, LDL cholesterol lowering, hyperlipidemia, statin therapy, apolipoprotein B, lipoprotein(a), cardiovascular events, injection site reactions, monoclonal antibody therapy, drug durability, treatment response heterogeneity, cardiovascular risk reduction
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Anticholesteremic Agents, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Injections, Subcutaneous, Lipids, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
